e-ISSN: Pending
Negative / Null Result ReportOpen accessPediatrics

Polypharmacy and pharmacogenomics in high-acuity behavioral health care for autism spectrum disorder: a retrospective study

Sheldon R. Garrison; Sophie A. Schweinert; Matthew W. Boyer; Maharaj Singh; Sreya Vadapalli; Jeffery M. Engelmann; Rachel A. Schwartz; Madeline M. Hartig · 2025 · Child and Adolescent Psychiatry and Mental Health

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Abstract Background This study evaluated pharmacogenomic (PGx) testing in children and adolescents with autism spectrum disorder (ASD). ASD frequently presents with co-occurring depression and anxiety. This complex phenotype often results in psychotropic medication polypharmacy. Incorporating PGx testing into the medical work-up may reduce polypharmacy and improve quality of life with symptom reduction. Methods A retrospective electronic health record (EHR) review between January 2017 and May 2023. Individuals either received PGx testing or treatment as usual (TAU). The co-primary outcomes wer

Abstract by Sheldon R. Garrison; Sophie A. Schweinert; Matthew W. Boyer; Maharaj Singh; Sreya Vadapalli; Jeffery M. Engelmann; Rachel A. Schwartz; Madeline M. Hartig, Child and Adolescent Psychiatry and Mental Health (2025) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1186/s13034-025-00915-3